Nektar Therapeutics (NKTR) AI Stock Analysis

• Market Cap: $2.10B
• Dividend Yield: N/A
• Average Volume (3M): 1.46M
• Price to Earnings (P/E): ―
• Beta (1Y): 3.78
• Revenue Growth: -32.79%
• EPS Growth: 36.87%
• Country: US
• Employees: 61
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.78
• Shares Outstanding: 28,687,963
• 10 Day Avg. Volume: 895,338
• 30 Day Avg. Volume: 1,458,199
• PEG Ratio: -0.36
• Price to Book (P/B): 7.94
• Price to Sales (P/S): 12.91
• P/FCF Ratio: -3.42
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: 29.59
• Enterprise Value/Gross Profit: 29.69
• Enterprise Value/Ebitda: -13.29
• 1Y Price Target: $127.39
• Price Target Upside: 74.08% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -10.25
• Revenue Forecast (FY): $39.24M

• Rating: 57 Neutral
• Price Target: $76.00 ▲(3.85% Upside)
• Action: Reiterated Date: 03/14/26
• Date: Action: Reiterated 03/14/26

The score is held back primarily by weak financial performance (recurring losses, declining 2025 revenue, and substantial cash burn). Offsetting this, technicals are strong with price well above key moving averages and supportive momentum, while the latest earnings call was positive on clinical progress and funding (enabling Phase 3) but tempered by higher 2026 spending guidance and execution risk.

Positive Factors

Proof-of-concept in Alopecia Areata

Topline Phase 2b data showing meaningful clinical effect and acceptable safety provides de-risking ahead of Phase 3. Proof-of-concept strengthens the program's regulatory and commercial prospects, improving partner interest and the long-term likelihood of a viable approved therapy.

Differentiated REZPEG data in Atopic Dermatitis + Asthma

Demonstrated efficacy in both skin disease and comorbid asthma suggests a differentiated mechanism and broader addressable market versus single-indication biologics. Durable competitive advantage could arise from treating multimorbid patients and driving higher long-term uptake and payer interest.

Standalone cash runway and cash position

A multi-quarter cash runway and absence of debt provide operational flexibility to complete near-term pivotal activities without immediate refinancing. This reduces short-term dilution risk and gives management time to deliver clinical catalysts that materially change financing needs or partnership options.

Negative Factors

High leverage on balance sheet

Material leverage increases financial vulnerability if development timelines slip or revenues underperform. High debt-to-equity and negative ROE constrain strategic options, raise financing costs, and can force unfavorable financing or asset sales, undermining long-term program execution.

Negative operating and free cash flow

Sustained negative operating cash flow signals ongoing burn from R&D and operations, making the company reliant on financing or partnerships. Persistent cash deficits erode runway, increase dilution risk, and limit ability to scale manufacturing or launch commercial programs post-approval.

Declining revenue and weak profitability

Ongoing revenue decline and negative margins reduce internal funding capacity for clinical programs and commercialization. Weak profitability undermines balance sheet resilience, heightens sensitivity to trial setbacks, and increases the probability of dilutive financing over the medium term.

Nektar Therapeutics Business Overview & Revenue Model

Company Description

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

How the Company Makes Money

Nektar Therapeutics primarily generates revenue from (1) collaboration and partnership arrangements and (2) royalties from partnered products, where applicable. Collaboration revenue can include upfront payments, research funding, and milestone payments tied to development, regulatory, or commercial events under agreements with other biopharmaceutical companies. Royalty revenue, when present, is earned as a percentage of net sales of products commercialized by partners that incorporate Nektar’s technology or originated from Nektar programs. Beyond these operating revenue sources, the company has historically relied on financing activities (such as issuing equity and/or debt) to fund research and development; however, financing proceeds are not operating revenue. Specific current products generating royalties, active collaborations, milestone structures, and the relative contribution of each stream are null.

Nektar Therapeutics Financial Statement Overview

Summary

Weak fundamentals driven by persistent operating/net losses and significant ongoing cash burn (2025 operating cash flow about -$208.5M; FCF about -$208.7M). Revenue declined materially in 2025 (~$55.2M vs ~$98.4M in 2024). Balance sheet leverage improved in 2025 and debt trended down, but equity has compressed and ROE remains strongly negative.

Income Statement

Revenue has been volatile and is down materially in 2025 (to ~$55.2M from ~$98.4M in 2024), following several years of uneven growth. Profitability remains weak with persistent, large operating losses and net losses every year shown; 2025 net margin is deeply negative (about -297%), reflecting a cost structure that is not yet supported by the current revenue base. A positive is that net losses narrowed meaningfully versus 2023–2022, but the business still lacks a clear path to sustained profitability based on these results.

Balance Sheet

Leverage is moderate but has become less comfortable as equity has declined: debt-to-equity moved from ~0.36 (2022) to ~1.69 (2024) before improving to ~0.95 (2025). Total debt has trended down versus prior years, which helps, but equity has also compressed sharply from earlier periods, reducing the balance-sheet cushion. Returns on equity are strongly negative throughout, consistent with ongoing losses and suggesting continued pressure on capital if operating performance doesn’t improve.

Cash Flow

Cash generation is a key weakness: operating cash flow and free cash flow are materially negative every year, including 2025 operating cash flow of about -$208.5M and free cash flow of about -$208.7M. While free cash outflow has improved substantially from 2021–2022 levels, the company is still consuming significant cash relative to its revenue base. Free cash flow has closely tracked net losses, indicating losses are translating into real cash burn rather than being primarily non-cash.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	55.23M	98.43M	90.12M	92.06M	101.91M
Gross Profit	55.23M	67.74M	53.48M	70.42M	77.01M
EBITDA	-129.74M	-86.70M	-243.11M	-323.87M	-461.82M
Net Income	-164.08M	-118.96M	-276.06M	-368.20M	-523.84M
Balance Sheet
Total Assets	280.41M	303.85M	398.03M	710.60M	1.12B
Cash, Cash Equivalents and Short-Term Investments	245.75M	255.23M	303.62M	504.98M	733.96M
Total Debt	148.91M	102.56M	117.78M	131.50M	143.18M
Total Liabilities	190.57M	243.11M	267.05M	343.96M	437.68M
Stockholders Equity	89.83M	60.74M	130.99M	366.64M	679.51M
Cash Flow
Free Cash Flow	-208.68M	-177.18M	-193.47M	-309.68M	-427.65M
Operating Cash Flow	-208.51M	-175.71M	-192.61M	-304.01M	-412.66M
Investing Cash Flow	-1.20M	142.57M	139.56M	365.83M	202.78M
Financing Cash Flow	180.57M	42.12M	30.00K	1.51M	36.24M

Nektar Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 73.18
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NKTR, the sentiment is Positive. The current price of 73.18 is above the 20-day moving average (MA) of 71.21, above the 50-day MA of 54.84, and above the 200-day MA of 44.06, indicating a bullish trend. The MACD of 4.63 indicates Positive momentum. The RSI at 61.18 is Neutral, neither overbought nor oversold. The STOCH value of 75.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NKTR.

Nektar Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRAX	67 Neutral	$8.04B	-21.87	-58.74%	―	364.98%	-25.33%
NKTR	57 Neutral	$2.10B	-5.95	-399.10%	―	-32.79%	36.87%
ORIC	57 Neutral	$1.09B	-5.55	-38.79%	―	―	4.29%
WVE	56 Neutral	$2.24B	-14.03	-84.99%	―	103.75%	33.84%
TRVI	56 Neutral	$1.37B	-42.49	-27.34%	―	―	15.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NUVB	50 Neutral	$1.49B	-14.96	-57.48%	―	1137.19%	70.51%

Nektar Therapeutics Corporate Events

Nektar Therapeutics Prices Upsized Public Equity Offering

On February 11, 2026, Nektar Therapeutics priced an upsized underwritten public offering of common stock and pre-funded warrants expected to raise about $400 million in gross proceeds and approximately $432 million in estimated net proceeds after underwriting discounts and expenses, following full exercise on February 12 of underwriters’ 30-day option for additional shares, with closing anticipated on February 13, 2026. All securities are being sold by the company under an effective shelf registration, and Nektar plans to use the capital for general corporate purposes including research and development, Phase 3 development for rezpegaldesleukin, and manufacturing to advance its immunotherapy pipeline, strengthening its funding position for late-stage clinical programs.

The most recent analyst rating on (NKTR) stock is a Buy with a $151.00 price target. To see the full list of analyst forecasts on Nektar Therapeutics stock, see the NKTR Stock Forecast page.

Nektar Advances Rezpegaldesleukin After Positive Phase 2b Data

On February 10, 2025, Nektar Therapeutics reported positive 36-week blinded maintenance results from its 52-week Phase 2b REZOLVE-AD trial of rezpegaldesleukin in 393 patients with moderate-to-severe atopic dermatitis. Monthly and quarterly dosing of the Treg biologic maintained robust EASI-75, EASI-90, vIGA-AD 0/1 and itch responses at week 52, highlighted by 71% and 83% EASI-75 maintenance rates for 24 µg/kg monthly and quarterly dosing, respectively.

The study also showed meaningful deepening of response over time, including two- to five-fold increases in complete clearance (EASI-100) rates, with conversions up to 30% among certain responder subsets by week 52. Rezpegaldesleukin’s safety profile remained favorable and consistent with induction, with low discontinuations and mostly mild injection-site reactions, supporting its potential as a differentiated, less frequently dosed therapy and underpinning Nektar’s move toward Phase 3 development in atopic dermatitis.

The most recent analyst rating on (NKTR) stock is a Buy with a $105.00 price target. To see the full list of analyst forecasts on Nektar Therapeutics stock, see the NKTR Stock Forecast page.

Nektar Therapeutics Announces Phase 2b Trial Results

On December 16, 2025, Nektar Therapeutics announced the topline results from the 36-week induction treatment period of its Phase 2b REZOLVE-AA trial for the treatment of severe-to-very-severe alopecia areata. The trial demonstrated that both doses of rezpegaldesleukin more than doubled the reduction in the Severity of Alopecia Tool (SALT) score compared to placebo, with the primary endpoint narrowly missing statistical significance. However, when excluding four patients with major eligibility violations, the treatment achieved statistical significance. The study showed a favorable safety profile, with most adverse events being mild-to-moderate and self-resolving. These results establish a proof-of-concept for rezpegaldesleukin and support its advancement to Phase 3 development.

The most recent analyst rating on (NKTR) stock is a Hold with a $58.00 price target. To see the full list of analyst forecasts on Nektar Therapeutics stock, see the NKTR Stock Forecast page.